Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 3.27
PDLI's Cash-to-Debt is ranked lower than
66% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. PDLI: 3.27 )
Ranked among companies with meaningful Cash-to-Debt only.
PDLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.84 Max: No Debt
Current: 3.27
0.25
No Debt
Equity-to-Asset 0.75
PDLI's Equity-to-Asset is ranked higher than
60% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PDLI: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
PDLI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.93  Med: 0.62 Max: 0.98
Current: 0.75
-1.93
0.98
Debt-to-Equity 0.17
PDLI's Debt-to-Equity is ranked higher than
64% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. PDLI: 0.17 )
Ranked among companies with meaningful Debt-to-Equity only.
PDLI' s Debt-to-Equity Range Over the Past 10 Years
Min: -250.06  Med: 0.29 Max: 18.48
Current: 0.17
-250.06
18.48
Debt-to-EBITDA -5.69
PDLI's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. PDLI: -5.69 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PDLI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.69  Med: 1.12 Max: 2.65
Current: -5.69
-5.69
2.65
Interest Coverage 5.10
PDLI's Interest Coverage is ranked lower than
91% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 5.10 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s Interest Coverage Range Over the Past 10 Years
Min: 4.85  Med: 12.37 Max: 19.15
Current: 5.1
4.85
19.15
Piotroski F-Score: 3
Altman Z-Score: 2.69
Beneish M-Score: -1.84
WACC vs ROIC
4.21%
15.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 40.59
PDLI's Operating Margin % is ranked higher than
95% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. PDLI: 40.59 )
Ranked among companies with meaningful Operating Margin % only.
PDLI' s Operating Margin % Range Over the Past 10 Years
Min: 40.59  Med: 93.2 Max: 94.93
Current: 40.59
40.59
94.93
Net Margin % -32.35
PDLI's Net Margin % is ranked higher than
61% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. PDLI: -32.35 )
Ranked among companies with meaningful Net Margin % only.
PDLI' s Net Margin % Range Over the Past 10 Years
Min: -32.35  Med: 55.8 Max: 60.49
Current: -32.35
-32.35
60.49
ROE % -8.36
PDLI's ROE % is ranked higher than
72% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. PDLI: -8.36 )
Ranked among companies with meaningful ROE % only.
PDLI' s ROE % Range Over the Past 10 Years
Min: -8.36  Med: 72.89 Max: 1166.18
Current: -8.36
-8.36
1166.18
ROA % -5.81
PDLI's ROA % is ranked higher than
74% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. PDLI: -5.81 )
Ranked among companies with meaningful ROA % only.
PDLI' s ROA % Range Over the Past 10 Years
Min: -5.81  Med: 38.25 Max: 77.05
Current: -5.81
-5.81
77.05
ROC (Joel Greenblatt) % -504.56
PDLI's ROC (Joel Greenblatt) % is ranked higher than
51% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. PDLI: -504.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PDLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -504.56  Med: 82080.42 Max: 1198273.12
Current: -504.56
-504.56
1198273.12
3-Year Revenue Growth Rate -14.40
PDLI's 3-Year Revenue Growth Rate is ranked lower than
66% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PDLI: -14.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PDLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22  Med: 13.4 Max: 65.5
Current: -14.4
-22
65.5
3-Year EBITDA Growth Rate -22.00
PDLI's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. PDLI: -22.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PDLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15 Max: 202.9
Current: -22
0
202.9
3-Year EPS without NRI Growth Rate -27.50
PDLI's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. PDLI: -27.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PDLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -43.2 Max: 89.5
Current: -27.5
0
89.5
GuruFocus has detected 5 Warning Signs with PDL BioPharma Inc PDLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PDLI's 30-Y Financials

Financials (Next Earnings Date: 2018-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

PDLI Guru Trades in Q3 2017

Chuck Royce 4,302 sh (New)
Jim Simons 11,131,786 sh (+3.99%)
Charles Brandes 1,112,679 sh (+0.48%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 23,201 sh (-8.61%)
» More
Q4 2017

PDLI Guru Trades in Q4 2017

Pioneer Investments 20,000 sh (New)
Chuck Royce 5,015 sh (+16.57%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Charles Brandes 1,100,518 sh (-1.09%)
Jim Simons 10,284,454 sh (-7.61%)
» More
Q1 2018

PDLI Guru Trades in Q1 2018

Paul Tudor Jones 21,351 sh (New)
Pioneer Investments 20,000 sh (unchged)
First Eagle Investment Sold Out
Jim Simons 9,648,854 sh (-6.18%)
Chuck Royce 4,622 sh (-7.84%)
Charles Brandes 820,741 sh (-25.42%)
» More
Q2 2018

PDLI Guru Trades in Q2 2018

Caxton Associates 45,069 sh (New)
Chuck Royce 8,036 sh (+73.86%)
Jim Simons 9,688,354 sh (+0.41%)
Pioneer Investments 20,000 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes 272,811 sh (-66.76%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2018-06-30 Reduce -66.76%0.03%$2.3 - $3.12 $ 2.43-13%272,811
Charles Brandes 2018-03-31 Reduce -25.42%0.02%$2.39 - $3.09 $ 2.43-11%820,741
First Eagle Investment 2018-03-31 Sold Out $2.39 - $3.09 $ 2.43-11%0
Charles Brandes 2017-12-31 Reduce -1.09%$2.74 - $3.51 $ 2.43-21%1,100,518
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Sold Out $2.74 - $3.51 $ 2.43-21%0
Charles Brandes 2017-09-30 Add 0.48%$2.17 - $3.4 $ 2.43-12%1,112,679
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -8.61%$2.17 - $3.4 $ 2.43-12%23,201
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:SHSE:603229, NAS:SVA, XKRX:182400, TSX:AUP, XKRX:053030, NAS:AKBA, SZSE:002604, XMCE:PHM, SZSE:002566, XPAR:IPH, NAS:OBSV, NAS:PRTA, NAS:CYTK, NAS:VCEL, NAS:SIGA, BSP:GBIO33, NAS:CNCE, ASX:CUV, OCSE:ZEAL, XKRX:196170 » details
Traded in other countries:PDL.Germany,
Headquarter Location:USA
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent.

PDL BioPharma Inc discovers and develops humanized monoclonal antibodies and receives royalties from nine marketed products licensed under PDL patents. The ESP Pharma acquisition brought marketed products to PDL in 2005, but because of a lack of strategic fit, PDL sold its commercial assets in early 2008. After paying a special dividend to shareholders, PDL has spun off its drug-discovery and -development business and plans to continue distributing royalty-based income to shareholders.

Ratios

vs
industry
vs
history
Forward PE Ratio 10.56
PDLI's Forward PE Ratio is ranked higher than
96% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. PDLI: 10.56 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.48
PDLI's PB Ratio is ranked higher than
98% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. PDLI: 0.48 )
Ranked among companies with meaningful PB Ratio only.
PDLI' s PB Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.71 Max: 38.99
Current: 0.48
0.43
38.99
PS Ratio 1.76
PDLI's PS Ratio is ranked higher than
90% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 1.76 )
Ranked among companies with meaningful PS Ratio only.
PDLI' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 2.87 Max: 15.85
Current: 1.76
0.87
15.85
EV-to-EBIT -1.55
PDLI's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. PDLI: -1.55 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.6  Med: 3.3 Max: 10.5
Current: -1.55
-2.6
10.5
EV-to-EBITDA -3.71
PDLI's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. PDLI: -3.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
PDLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: 3.2 Max: 7.8
Current: -3.71
-6.2
7.8
EV-to-Revenue 0.39
PDLI's EV-to-Revenue is ranked higher than
99% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. PDLI: 0.39 )
Ranked among companies with meaningful EV-to-Revenue only.
PDLI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 3.2 Max: 11.5
Current: 0.39
0.2
11.5
Shiller PE Ratio 2.07
PDLI's Shiller PE Ratio is ranked higher than
93% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. PDLI: 2.07 )
Ranked among companies with meaningful Shiller PE Ratio only.
PDLI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.78  Med: 3.76 Max: 209.25
Current: 2.07
1.78
209.25
Current Ratio 11.13
PDLI's Current Ratio is ranked higher than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PDLI: 11.13 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 9.88 Max: 76.07
Current: 11.13
0.26
76.07
Quick Ratio 10.80
PDLI's Quick Ratio is ranked higher than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. PDLI: 10.80 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 9.76 Max: 76.07
Current: 10.8
0.26
76.07
Days Inventory 92.64
PDLI's Days Inventory is ranked higher than
62% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. PDLI: 92.64 )
Ranked among companies with meaningful Days Inventory only.
PDLI' s Days Inventory Range Over the Past 10 Years
Min: 71.9  Med: 100.69 Max: 129.48
Current: 92.64
71.9
129.48
Days Sales Outstanding 34.10
PDLI's Days Sales Outstanding is ranked higher than
76% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. PDLI: 34.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.21  Med: 0.6 Max: 68.46
Current: 34.1
0.21
68.46
Days Payable 84.27
PDLI's Days Payable is ranked higher than
57% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. PDLI: 84.27 )
Ranked among companies with meaningful Days Payable only.
PDLI' s Days Payable Range Over the Past 10 Years
Min: 84.27  Med: 433.23 Max: 629.97
Current: 84.27
84.27
629.97

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
PDLI's 3-Year Dividend Growth Rate is ranked lower than
83% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. PDLI: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PDLI' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -45
Current: -100
3-Year Average Share Buyback Ratio 1.80
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. PDLI: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -5.5 Max: 1.8
Current: 1.8
-7.9
1.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.19
PDLI's Price-to-Net-Cash is ranked higher than
85% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. PDLI: 2.19 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PDLI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.12  Med: 13.41 Max: 205.5
Current: 2.19
1.12
205.5
Price-to-Net-Current-Asset-Value 1.29
PDLI's Price-to-Net-Current-Asset-Value is ranked higher than
93% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. PDLI: 1.29 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PDLI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.1  Med: 4.84 Max: 71.33
Current: 1.29
1.1
71.33
Price-to-Tangible-Book 1.10
PDLI's Price-to-Tangible-Book is ranked higher than
93% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. PDLI: 1.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PDLI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86  Med: 2.67 Max: 47.78
Current: 1.1
0.86
47.78
Price-to-Intrinsic-Value-Projected-FCF 0.16
PDLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. PDLI: 0.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PDLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.13  Med: 2.48 Max: 90.82
Current: 0.16
0.13
90.82
Price-to-Median-PS-Value 0.61
PDLI's Price-to-Median-PS-Value is ranked higher than
72% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. PDLI: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PDLI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 3.77 Max: 32.21
Current: 0.61
0.37
32.21
Earnings Yield (Greenblatt) % -64.92
PDLI's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. PDLI: -64.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PDLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -97.29  Med: 29.7 Max: 265.1
Current: -64.92
-97.29
265.1
Forward Rate of Return (Yacktman) % 28.97
PDLI's Forward Rate of Return (Yacktman) % is ranked higher than
94% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. PDLI: 28.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PDLI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 18.8 Max: 71.3
Current: 28.97
-8.7
71.3

More Statistics

Revenue (TTM) (Mil) $209.05
EPS (TTM) $ -0.46
Beta0.11
Volatility36.34%
52-Week Range $2.25 - 3.55
Shares Outstanding (Mil)145.40

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 176 145
EBIT (Mil $)
EBITDA (Mil $) 54 39
EPS ($) -0.60 0.13
EPS without NRI ($) -0.60 0.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}